AbbVie Inc. (ABBV)
Why I Can't Stop Buying This Unstoppable Dividend Juggernaut
I hit the buy button on AbbVie (NYSE:ABBV | ABBV Price Prediction) again last week, and I will hit it again the next time June's macro noise hands me a discount.
AbbVie's $11 Billion Immunology Bet
In this week's edition of InnovationRx, we look at AbbVie's new megadeal, an agentic AI startup saving Medicare $2 million a week, how new student loan rules could degrade healthcare and more. To get it in your inbox, subscribe here.
AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis
ABBV gains EU approval for Skyrizi in pediatric plaque psoriasis, expanding reach in younger patients with a new weight-based dosing option.
After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching
Biotech M&A is back in the spotlight. Big Pharma faces patent cliffs over the next several years, and recent dealmaking, including the AbbVie (NYSE: ABBV | ABBV Price Prediction) acquisition of Apogee Therapeutics, signals buyers are willing to pay up for de-risked clinical assets in oncology, obesity, and cell therapy.
ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout
AbbVie shares jump after its $10.9B Apogee deal adds late-stage eczema and respiratory candidates, deepening its immunology pipeline.
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal
Big pharma's appetite for clinical-stage biotech is back. The pending acquisition of Apogee Therapeutics by AbbVie (NYSE: ABBV | ABBV Price Prediction), targeting an atopic dermatitis and immunology developer, has reignited a question every healthcare portfolio manager is asking: who will be next?
AbbVie Inc. (ABBV) M&A Call Transcript
AbbVie Inc. (ABBV) M&A Call Transcript
AbbVie and Merck Face-Off: Which Pharma Stock Has the Lead?
ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.
AbbVie to Buy Apogee Therapeutics for $10.9 Billion
Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, commonly known as eczema, to its portfolio.
AbbVie to acquire Apogee Therapeutics in $10.9B deal
Abbvie Inc (NYSE:ABBV) announced that it will acquire Apogee Therapeutics (NASDAQ:APGE) in an all-cash transaction valued at approximately $10.9 billion, adding a pipeline of clinical-stage therapies for inflammatory and immunological diseases, including atopic dermatitis and asthma. Under the terms of the definitive agreement announced Sunday, AbbVie will acquire all outstanding Apogee shares for $135.11 per share in cash.
5 Things to Know Before the Stock Market Opens
Stocks are having a quiet morning Monday as investors come off a long holiday weekend with a close eye on peace talks between the U.S. and Iran; a second day of negotiations in Switzerland has reportedly concluded after renewed threats against Iran from President Trump and continued attacks in Lebanon by Israel made for an eventful first day of talks; earnings from FedEx and Micron are on tap this week, along with the release of the Fed's preferred measure of inflation; SpaceX shares are poised to start this week with a third straight day of declines; and shares of Apogee Therapeutics are soaring on news it is being acquired by AbbVie for $11 billion. Here's what you need to know today.
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company's immunology and inflammation portfolio.
